Press release
Biotage Unveils New Fully Automated Microwave Peptide Synthesizer
Uppsala, Sweden, September 25, 2012 -- Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced an innovative new synthesis platform for peptide researchers at the 2012 European Peptide Symposium in Athens, Greece. The Biotage® Initiator+ Alstra is a fully automated, single channel, programmable microwave peptide synthesizer and is the latest addition to Biotage's growing family of peptide synthesis platforms.The Initiator+ Alstra is an ideal tool for peptide chemists synthesizing peptides, peptoids, PNA and peptidomimetics, including extremely difficult modifications. The system's inherent flexibility for reagent set-up, makes it a highly effective platform for both small and large scale synthesis from 5 µmol to 2 mmol. With a working volume from as low as 0.6 mL, the Initiator+ Alstra is perfectly suited for small scale microwave peptide synthesis, especially when the use of expensive building blocks is required e.g. PNA. The system's robotic liquid handler and precise digital syringe pumps reduce reagent and solvent consumption, thus reducing cost and minimizing waste.
The Initiator+ Alstra is programmable via a large 10" touch screen with drag and drop functionality for optimizing pre-installed or user defined methods. A built-in wizard makes programming a synthesis sequence effortless and a calculation table, which is generated, provides the quantities of reagents required, allowing the user to very quickly go from an idea to execution.
"Initiator+ Alstra is an extremely simple to use work horse which fills an important gap in the toolbox of the Peptide researcher. Its state of the art interface, simplicity of operation, speed, size and price are all optimized to match the increasing demands which Peptide Chemists are under today", say's Dr. Amit Mehrotra, Peptide Product Manager at Biotage. "This product is the result of customer input and demands and we are very excited to now be putting it into their hands".
For further information visit http://www.biotage.com or call:
In Europe: +46 18 56 57 10
In North America: (Toll Free) 1 800 446 4752
In Japan: +81 422 28 1233
Other areas, please call: +46 18 56 57 10.
-Ends-
About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. Customers include the world’s top pharmaceutical and biotechnology companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, with offices in China, Japan, the United Kingdom, the United States and a worldwide network of distributors. Biotage has 272 employees with sales of 428.9 MSEK in 2010. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange. Website: http://www.biotage.com.
For further press information at Biotage please contact:
James Churchill
Marketing Communications
Biotage GB Limited
Distribution Way
Dyffryn Business Park
Ystrad Mynach
Hengoed, Wales CF82 7TS
United Kingdom
Tel: +44 (0)1443 811 849
Mobile: +44(0)7875484778
E-Mail: james.churchill@biotage.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biotage Unveils New Fully Automated Microwave Peptide Synthesizer here
News-ID: 237432 • Views: …
More Releases from Biotage

Biotage® Announces EVOLUTE® EXPRESS Columns - Simplified, Fast and Efficient S …
Uppsala, Sweden -- Biotage® (STO: BIOT), a leading global supplier of solutions and technology for analytical and medicinal chemistry, announces the addition of new polymer based SPE columns to their tried and tested EVOLUTE® EXPRESS range.
EVOLUTE® EXPRESS is a novel family of plates, and now columns, that simplify polymer-based SPE by employing a streamlined three step protocol; Load-Wash-Elute. By using this approach and removing the conditioning and equilibration steps, necessary…

Biotage Launches ACI™ - Accelerated Chromatographic Isolation
Uppsala, Sweden (July 10, 2014) -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of ACI™ (Accelerated Chromatographic Isolation), a new advance converting simple flash purification into a faster and more economical way to isolate pure compounds.
Biotage believes that ACI™ will radically improve the efficiency of the laboratory, embracing the latest developments in purification technology to guide chemists…

Biotage Breaks New Ground with Its Fully Integrated Mass Directed Flash System
Uppsala, Sweden, June 5, 2013 -- Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, announces the launch of the new Isolera™ Dalton - a fully automated miniaturized mass directed flash purification system. The new system raises the bar for flash purification by integrating, for the first time, a miniaturized mass detector and an advanced flash chromatography system into one commercially available…
More Releases for Peptide
Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth…
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension…
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights:
• Global Peptide Cancer Drug Market Insight By Region & Indication
• Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion
• Approved Peptide Cancer Drugs: > 30 Drugs
• Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis
• Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase
• Insight On Peptide Cancer Drugs In Clinical Trials: >…
Growing Adoption of Synthetic Peptide Drugs Driving Peptide Therapeutics Market …
Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031).
[https://www.skyquestt.com/report/peptide-therapeutics-market] size was valued at USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). The increasing prevalence of…
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global…
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established…